Coya Therapeutics, Inc. (NASDAQ:COYA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Coya Therapeutics, Inc. (NASDAQ:COYA) have been assigned an average recommendation of “Moderate Buy” from the seven ratings firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $15.3333.

Several equities analysts have recently weighed in on the stock. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a research note on Friday, June 12th. Wall Street Zen downgraded shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Coya Therapeutics in a research report on Monday, March 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a report on Monday, April 20th. Finally, Roth Mkm started coverage on Coya Therapeutics in a research report on Friday, June 5th. They issued a “buy” rating and a $12.00 target price on the stock.

Coya Therapeutics Price Performance

Shares of Coya Therapeutics stock opened at $5.66 on Thursday. The firm has a market cap of $132.78 million, a price-to-earnings ratio of -4.92 and a beta of 0.50. The stock’s 50-day moving average is $4.75 and its 200-day moving average is $4.76. Coya Therapeutics has a one year low of $3.71 and a one year high of $7.75.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.07. The business had revenue of $0.25 million during the quarter, compared to the consensus estimate of $0.15 million. Coya Therapeutics had a negative return on equity of 55.86% and a negative net margin of 266.10%. On average, equities analysts expect that Coya Therapeutics will post -1.49 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Prosperity Wealth Management Inc. boosted its holdings in shares of Coya Therapeutics by 16.4% in the 3rd quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock valued at $136,000 after buying an additional 3,350 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in Coya Therapeutics during the third quarter worth $28,000. Cetera Investment Advisers raised its position in Coya Therapeutics by 36.4% during the first quarter. Cetera Investment Advisers now owns 30,000 shares of the company’s stock worth $118,000 after acquiring an additional 8,000 shares in the last quarter. CIBC Private Wealth Group LLC bought a new stake in Coya Therapeutics during the fourth quarter worth $47,000. Finally, Occudo Quantitative Strategies LP acquired a new stake in Coya Therapeutics in the fourth quarter valued at $66,000. Institutional investors and hedge funds own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.